Pfizer launched a clinical trial in March to study the safety and efficacy of Paxlovid in children and teenagers ages 6 to 17 who have COVID-19 symptoms and test positive for the virus, and who are neither hospitalized nor at risk for severe disease. hyperlipidemia. Co-administration with other CYP3A substrates may require a dose adjustment or additional monitoring.Nirmatrelvir and ritonavir are CYP3A substrates; therefore, drugs that induce CYP3A may decrease nirmatrelvir and ritonavir plasma concentrations and reduce PAXLOVID therapeutic effect.Pregnancy: There are no available human data on the use of nirmatrelvir during pregnancy to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Increased grazoprevir concentrations can result in ALT elevations. Liverpool COVID-19 Interactions Coadministration contraindicated due to potential for myopathy including rhabdomyolysis [see Contraindications (4)]. ticagrelor a Reduced effectiveness of clopidogrel is likely. Not all medications that may interact with ritonavir-boosted nirmatrelvir are included in Box 2. Paxlovid (nirmatrelvir and ritonavir) is an oral antiviral combination used to treat COVID-19. Official websites use .govA .gov website belongs to an official government organization in the United States. clopidogrel, aliskiren A transient decrease in body weight was observed in the nursing offspring of rats administered nirmatrelvir. Renal impairment reduces the clearance of nirmatrelvir. Consult the following resources for information on identifying and managing drug-drug interactions. Reply falcongsr . Minimally clinically significant. 2022. PAXLOVID must be prescribed by a licensed healthcare provider and supplied by a government-approved pharmacy or medical facility. Coadministration contraindicated due to potential loss of virologic response and possible resistance. Refer to individual product labels for more information. Available at: Charness ME, Gupta K, Stack G, et al. More than 120 medications have been flagged for interactions, and each case needs to be evaluated, taking into account an individual's conditions, as well as kidney and liver function. Paxlovid is an antiviral therapy that consists of two separate medications packaged together. Consider the potential for drug interactions prior to and during PAXLOVID therapy; review concomitant medications during PAXLOVID therapy and monitor for the adverse reactions associated with the concomitant medications. Published studies with ritonavir are insufficient to identify a drug-associated risk of miscarriage. PAXLOVID (nirmatrelvir tablets; ritonavir tablets) For HCPs Potential Paxlovid side effect: Metallic taste in mouth. For anyone who experiences a rebound, the CDC advises people restart isolation for five days, following its isolation guidance. reference. One of our biggest public health challenges is to decrease the rate of severe COVID-19 disease in the face of pandemic fatigue, dried up funding, misinformation, and a changing virus. Consult Table 1 of the Fact Sheet for Healthcare Providers for clinically significant drug interactions, including contraindicated drugs. Paxlovid can interact with several other types of drugs, including organ anti-rejection drugs, medications used to treat heart arrhythmias, and systemic corticosteroids like betamethasone, dexamethasone, and prednisone (these corticosteroid interactions increase the risk for Cushing's syndrome, a disorder involving the hormone cortisol, and . Refer to the individual immunosuppressant product label for further information and obtain expert consultation from the patients immunosuppressive therapy specialist. Pfizer is committed to patient safety and ensuring that people have accurate information about the investigationaldrug PAXLOVID, including how it is accessed and administered. Nirmatrelvir and ritonavir are CYP3A4 substrates.